OIG Telehealth Fraud Concerns
In September 2022, the U.S. Department of Health and Human Services Office of Inspector General (OIG) put out a report on program integrity risks concerning Medicare telehealth services during the first year of the COVID-19 pandemic. The OIG states that in the first year of the pandemic, more than 28 million Medicare beneficiaries (roughly 2 in 5) used telehealth – amounting to a dramatic 88-fold increase from the previous year. Because of this, the OIG wanted to find out if providers were appropriately billing telehealth services, while looking to identify the best way to further protect the Medicare program and beneficiaries from fraud, waste, and abuse (FWA).
The OIG did some brief data analysis of telehealth claims from March 1, 2020 through February 28, 2021 of 742,000 providers. They found that 1,714 providers posed a high risk to Medicare due to concerning billing practices like; billing for services that were not medically necessary or that were never provided. Other reasons for scrutiny included being in the same medical practice as another provider who engaged in high-risk billing practices (i.e., guilt by association).
High risk providers were identified by the OIG when they billed:
- Both a telehealth service and a facility fee for most visits
- Telehealth services at the highest, most expensive level every time
- Telehealth services for a high number of days in a year
- Both Medicare fee-for-service and a Medicare Advantage plan for the same service for a high proportion of services
- A high average number of hours of telehealth services per visit
- Telehealth services for a high number of beneficiaries
- For a telehealth service and ordering medical equipment for a high proportion of beneficiaries
The OIG’s recommendations to CMS included strengthening target oversight and monitoring of telehealth services, providing education on appropriate billing for providers, improving transparency, identifying companies who provide telehealth to Medicare beneficiaries, and following up with providers identified in the OIG report as high risk.
PAAS Tips:
- Insulin Pens: Understanding Dosing Increments and Audit Risks - October 9, 2024
- What to Do (and Not Do) When Your Days’ Supply is Rejected - October 7, 2024
- 2024 DMEPOS Series #7: Therapeutic Shoes for Diabetics - September 5, 2024